Drugs / LOTAMILAST
LOTAMILAST
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03415282 | Feb → Jul 2018 | atopic eczema | Dermavant Sciences GmbH | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02094235 | Jan → Dec 2014 | atopic eczema | Organon and Co | Completed | No outcome recorded |
| Phase 1/2 | NCT01179880 | Sep 2010 → Dec 2012 | atopic eczema | Organon and Co | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03394677 | Jan → Jul 2018 | atopic eczema | Dermavant Sciences GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02950922 | Nov 2016 → Jul 2017 | atopic eczema | Dermavant Sciences GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01461941 | Dec 2011 → Nov 2012 | atopic eczema | Organon and Co | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-11-20 | Eisai Inc. | EISAI LICENSES SELECTIVE PHOSPHODIESTERASE 4 INHIBITOR E6005 TO ROIVANT SCIENCES eisai.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LOTAMILAST | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989967 ↗ |
| Known as | E6005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01461941 ↗ |
| Known as | RVT-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03415282 ↗ |
| Action | Inhibit | “a novel phosphodiesterase inhibitor, E6005” PMID 26581111 ↗ Nov 2015 |
| Modality | Small molecule | — CHEMBL3989967 ↗ |
| Route | Topical | “topical application of E6005 ointment” PMID 26581111 ↗ Nov 2015 |